Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Blood (2024) 144 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2024-212141

Published: 2024

Journal Articles

Chronic graft-versus-host disease: unresolved complication or ancient history?

Joseph A. Pidala, Ted A. Gooley, Leo Luznik, Bruce R. Blazar

Blood (2024) 144 (13): 1363–1373.

https://doi.org/10.1182/blood.2023022735

Published: 2024

Includes: Supplemental data

Journal Articles

CD8 + T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia

Francesco Mazziotta, Luca Biavati, Joseph Rimando, Sergio Rutella, Nicholas Borcherding, Sonali Parbhoo, Rupkatha Mukhopadhyay, Sayan Chowdhury, Hanna A. Knaus, Peter Valent, Hubert Hackl, Ivan M. Borrello, Bruce R. Blazar, Katerina Hatzi, Ivana Gojo, Leo Luznik

Blood (2024) 144 (11): 1168–1182.

https://doi.org/10.1182/blood.2023021680

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Jonathan Allen Webster, Richard J. Jones, Amanda Blackford, Audra Shedeck, Richard F. Ambinder, Lode J. Swinnen, Nina Wagner-Johnston, Ephraim Joseph Fuchs, Javier Bolanos-Meade, Philip Imus, Challice L. Bonifant, Heather Jill Symons, Tania Jain, Gabrielle T. Prince, Mark J. Levis, Leo Luznik, Ivana Gojo

Blood (2023) 142 (Supplement 1): 3582.

https://doi.org/10.1182/blood-2023-191047

Published: 2023

Journal Articles

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Joseph Rimando, Francesco Mazziotta, Alison Gareau, Maria Bettinotti, Jonathan Allen Webster, Syed Abbas Ali, Philip Imus, Mario Victor Lemas, Amy E. DeZern, Mark J. Levis, Marianna Zahurak, Ravi Varadhan, Richard F. Ambinder, Carol Huff, Ivana Gojo, Richard J. Jones, Ivan M. Borrello, Leo Luznik

Blood (2023) 142 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2023-179394

Published: 2023

Journal Articles

Blinatumomab in Combination with Immune Checkpoint Inhibitors (ICIs) of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Results of a Phase I Study

Jonathan Allen Webster, Marlise R. Luskin, Joseph Rimando, Amanda Blackford, Amer M. Zeidan, Elad Sharon, Howard Streicher, Daniel J. DeAngelo, Leo Luznik, Ivana Gojo

Blood (2023) 142 (Supplement 1): 966.

https://doi.org/10.1182/blood-2023-191109

Published: 2023

Journal Articles

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Amy E. DeZern, Marianna Zahurak, Heather J. Symons, Kenneth R. Cooke, Carol Ann Huff, Tania Jain, Lode J. Swinnen, Philip H. Imus, Nina D. Wagner-Johnston, Richard F. Ambinder, Mark Levis, Leo Luznik, Javier Bolaños-Meade, Ephraim J. Fuchs, Richard J. Jones, Robert A. Brodsky

Blood (2023) 141 (25): 3031–3038.

https://doi.org/10.1182/blood.2023020435

Published: 2023

Includes: Supplemental data

Journal Articles

How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond

Joseph Rimando, Shannon R. McCurdy, Leo Luznik

Blood (2023) 141 (1): 49–59.

https://doi.org/10.1182/blood.2021015129

Published: 2023

Includes: Supplemental data

Journal Articles

Different Subsets of Exhausted and Senescent-like T Cells Correlate with Response and Survival in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Francesco Mazziotta, Luca Biavati, Sonali Parbhoo, Sayan Chowdhury, Joseph Rimando, Ivan M. Borrello, Katerina Hatzi, Bruce R. Blazar, Ivana Gojo, Leo Luznik

Blood (2022) 140 (Supplement 1): 9132–9133.

https://doi.org/10.1182/blood-2022-167107

Published: 2022

Journal Articles

Alternative Reduced Intensity Conditioning for Allogeneic Blood and Marrow Transplantation Using Pentostatin, Cyclophosphamide, and Total-Body Irradiation with Post-Transplant Cyclophosphamide

Timothy J. Porter, Haval Norman, Javier Bolanos-Meade, Leo Luznik, Jamie E. Ziggas, Amy E. DeZern, Ephraim J. Fuchs, Richard J. Jones

Blood (2022) 140 (Supplement 1): 7601–7602.

https://doi.org/10.1182/blood-2022-166641

Published: 2022

Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Blood (2022) 140 (Supplement 1): 4813–4815.

https://doi.org/10.1182/blood-2022-171038

Published: 2022

Journal Articles

The Composition of Acute Myeloid Leukemia Cell Differentiation States Predicts Response to Immune Checkpoint Blockade

Joseph Rimando, Leslie Cope, Karen McKinnon, Benjamin G. Vincent, Sergio Rutella, Joshua F. Zeidner, Jonathan S. Serody, Ivana Gojo, Leo Luznik

Blood (2022) 140 (Supplement 1): 6314–6315.

https://doi.org/10.1182/blood-2022-165458

Published: 2022

Journal Articles

BET-bromodomain and EZH2 inhibitor–treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes

Blood (2022) 139 (19): 2983–2997.

https://doi.org/10.1182/blood.2021014557

Published: 2022

Includes: Supplemental data

Journal Articles

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

Shannon R. McCurdy, Vedran Radojcic, Hua-Ling Tsai, Ante Vulic, Elizabeth Thompson, Sanja Ivcevic, Christopher G. Kanakry, Jonathan D. Powell, Brian Lohman, Djamilatou Adom, Sophie Paczesny, Kenneth R. Cooke, Richard J. Jones, Ravi Varadhan, Heather J. Symons, Leo Luznik

Blood (2022) 139 (4): 608–623.

https://doi.org/10.1182/blood.2021013054

Published: 2022

Includes: Supplemental data

Journal Articles

Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia

Sergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, Stephen Reeder, Tung On Yau, Rupkatha Mukhopadhyay, Heidi Altmann, Michael Kramer, Hanna A. Knaus, Joshua F. Zeidner, Vedran Radojcic, Andrea Arruda, Mark D. Minden, Sarah K Tasian, Martin Bornhäuser, Ivana Gojo, Leo Luznik

Blood (2021) 138 (Supplement 1): 223.

https://doi.org/10.1182/blood-2021-145854

Published: 2021

Journal Articles

Bone Marrow GZMK + IL7R + Progenitor-Exhausted CD8 + T Cells Correlate with Sustained Clinical Remission in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Francesco Mazziotta, Luca Biavati, Rupkatha Mukhopadhyay, Hanna A. Knaus, Ivan M. Borrello, Ivana Gojo, Leo Luznik

Blood (2021) 138 (Supplement 1): 521.

https://doi.org/10.1182/blood-2021-149150

Published: 2021

Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Blood (2021) 138 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2021-153750

Published: 2021

Journal Articles

An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Tung On Yau, Heidi Altmann, PhD, Sarah E. Church, PhD, Hanna A Knaus, MD, Mark D. Minden, Jan K Davidson-Moncada, MDPhD, Sarah K Tasian, MD, Martin Bornhäuser, MD, Ivana Gojo, MD, Leo Luznik, MD, Sergio Rutella, MDPhDFRCPath

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134779

Published: 2020

Journal Articles

BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Sumithra Vasu, MDMBBS, Nelli Bejanyan, MD, Steven M Devine, MD, Elizabeth O. Hexner, MD MSTR, Brent Logan, PhD, Leo Luznik, MD, Brittany K. Ragon, MD, Andrew Sandler, MD, Elizabeth F Krakow, MDMSc, Michael Fitzgerald, Lorraine Tracey, PhD, Richard E. Champlin, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-134408

Published: 2020

Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141294

Published: 2020

NARROW

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Chronic graft-versus-host disease: unresolved complication or ancient history?

CD8 + T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Blinatumomab in Combination with Immune Checkpoint Inhibitors (ICIs) of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Results of a Phase I Study

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond

Different Subsets of Exhausted and Senescent-like T Cells Correlate with Response and Survival in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Alternative Reduced Intensity Conditioning for Allogeneic Blood and Marrow Transplantation Using Pentostatin, Cyclophosphamide, and Total-Body Irradiation with Post-Transplant Cyclophosphamide

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

The Composition of Acute Myeloid Leukemia Cell Differentiation States Predicts Response to Immune Checkpoint Blockade

BET-bromodomain and EZH2 inhibitor–treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia

Bone Marrow GZMK + IL7R + Progenitor-Exhausted CD8 + T Cells Correlate with Sustained Clinical Remission in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia

BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only